ERX Eirx Therap.

RNS Number:9957P
EiRx Therapeutics PLC
13 March 2008

                             EIRX THERAPEUTICS  PLC
                          ( "EiRx" or "the Company" )

                         Restoration of trading on AIM
                                      and
                                Business update

The Directors of EiRx Therapeutics plc are pleased to note the restoration of
the Company's shares to trading on AIM.

The Company can confirm that the suspension affected neither the Company's
business nor the fundraising announced on 19 February 2008.

Business Update

As part of the Company's ongoing efforts to streamline its organisation and
focus expenditure on critical activities necessary for value enhancement, EiRx
is this month closing its Aberdeen facility and relocating the operations of its
Auvation subsidiary to Cork.  These activities include the cancer biomarker
effort undertaken in collaboration with bioMerieux SA, and revenue generation
from licensing of laboratory research reagents.  The ACCRI-BANK tissue specimen
collection remains housed within the Pathology Department at the University of
Aberdeen Medical School, and the conditions of the Company's access to this
resource are unchanged.

Interim results

The Company will announce its results for the six months ended 31 December 2007
on 28 March 2008.

Commenting on recent events, EiRx CEO Colin Telfer said:

" With the benefit of the fundraising announced in February, we look forward to
advancing the Company's lead product programmes into medicinal chemistry via our
collaboration with Professor Anita Maguire and the Analytical and Biological
Chemistry Research Facility (ABCRF) at University College Cork. The Company will
also continue to drive expansion and deployment of the EnPADTM drug discovery
engine as well as seeking licensing and other business development
opportunities."

For further information, please contact:

EiRx Therapeutics plc                                 +353 (0)21 432 0847
Colin Telfer PhD, Chief Executive Officer
Grant Thornton Corporate Finance                      +44 (0)20 7383 5100
Philip Secrett / Colin Aaronson



About EiRx

EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing
cutting-edge targeted therapies for the treatment of cancer.  Headquartered in
Cork, Ireland, the Company conducts drug discovery focused on tumours arising
due to anomalies in apoptosis and cellular growth regulatory pathways, with
particular relation to breast and colorectal tumours, currently two of the four
leading causes of death from cancer world-wide.

EiRx is built on leading scientific expertise in the areas of apoptosis biology,
cancer pathway biology, biomarker technologies and the metabolic basis of drug
resistance in tumours.  It has established technical capabilities in target
identification, validation and cell-based screening, and is combining unique
resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional
genomics platform and the Engineered Pathway Dependence ("EnPADTM") isogenic
cellular screening technology to create a product development engine
specialising in discovery and development of small-molecule targeted cancer
therapies and the discovery and validation of cancer biomarkers.



For further information please see our website at http://www.eirx.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

STRILFIAVTIFLIT

Eirx Therapeutics (LSE:ERX)
Historical Stock Chart
From May 2024 to Jun 2024

Eirx Therapeutics (LSE:ERX)
Historical Stock Chart
From Jun 2023 to Jun 2024